Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30819028 | 0.87 | TACR1 (0.58) | TACR1KMT2AMEN1DDB1CRBN | |
| SCHEMBL5133293 | 0.81 | TACR1 (0.53) | TACR1KMT2AMEN1DRD4ALDH1A1 | |
| SCHEMBL5132526 | 0.81 | TACR1 (0.53) | TACR1KMT2AMEN1DRD4ALDH1A1 | |
| SCHEMBL28120391 | 0.80 | TACR1 (0.51) | TACR1KMT2AMEN1DDB1CRBN | |
| SCHEMBL15922327 | 0.80 | TACR1 (0.51) | TACR1KMT2AMEN1DDB1CRBN | |
| SCHEMBL12208454 | 0.80 | TACR1 (0.51) | TACR1KMT2AMEN1DDB1CRBN | |
| SCHEMBL5667214 | 0.79 | TACR1 (0.56) | TACR1HPGDALDH1A1 | |
| SCHEMBL5968243 | 0.79 | TACR1 (0.56) | TACR1HPGDALDH1A1 | |
| SCHEMBL1551999 | 0.79 | TACR1 (0.56) | TACR1KMT2AMEN1 | |
| SCHEMBL1553056 | 0.79 | TACR1 (0.56) | TACR1KMT2AMEN1POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120289502-A1 | IMIDAZOLE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-11-15 | — | — | US | disclosed |
| US-8273738-B2 | Imidazole derivatives | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-09-25 | — | — | US | disclosed |
| EP-2090570-B1 | IMIDAZOLE DERIVATIVE | KYOWA HAKKO KIRIN CO LTD (JP) | 2011-11-09 | — | — | EP | disclosed |
| US-20100152178-A1 | IMIDAZOLE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-06-17 | — | — | US | disclosed |
| EP-2090570-A1 | IMIDAZOLE DERIVATIVE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2009-08-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289502-A1 | IMIDAZOLE DERIVATIVES | CNR1, CNR2, ARRB1 | TACR1 169/4885KMT2A 1540/4885MEN1 3667/4885 |
| US-20100152178-A1 | IMIDAZOLE DERIVATIVES | CNR1, CNR2, ARRB1 | TACR1 169/4885KMT2A 1540/4885MEN1 3667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.